Full-Life Technologies and Eckert & Ziegler Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Jan 23, 2024

Gembloux, Belgium and Berlin, Germany – Jan. 23, 2024 – Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company and Eckert & Ziegler (ISIN DE0005659700, SDAX) today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access to Eckert & Ziegler's high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals.

Ac-225 has emerged as a highly promising active agent for the treatment of cancer. The radioisotope releases potent alpha particles with high energy and short penetration depths, allowing for precise targeting of tumor cells, including hard-to-reach micro-metastases, while minimizing impact on surrounding healthy tissue. Based on its potential, clinical and industry experts expect a substantial increase in Ac-225 demand in the coming decade.

“Ac-225 constitutes an essential element within our portfolio of therapeutic compounds, including our lead candidate, 225Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer,” stated Philippe van Put, General Manager of Full-Life Technologies Europe. “Securing access is imperative for advancing our development and clinical research efforts. Eckert & Ziegler brings great expertise and more than three decades of experience as a radioisotope specialist in support of our ambitious development initiatives.”

“We are delighted to have forged a supply collaboration with Full-Life Technologies, dedicating ourselves to facilitating their journey in clinical development,” said Dr Harald Hasselmann, CEO of Eckert & Ziegler. “Historically, limited Ac-225 supply has impeded progress in both clinical research and commercial applications. With the establishment of our new Ac-225 production facility, we aim to significantly increase access to this important radionuclide, with ramp up at the new facility occurring in the second half of the year.”

About Full-Life Technologies
Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.


Media Contacts:


Email: pr@t-full.com

Website: www.full-life.com 


Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de  / jan.schoepflin@ezag.de 
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

For the Media

We welcome media inquiries. Please indicate your deadline on the subject line.